丽珠医药口服GnRH拮抗剂II期临床成功,为辅助生殖带来更稳定便捷的治疗方案

动脉网
Jan 12

丽珠医药(深交所代码:000513;香港联交所代码:01513)宣布其引进的口服GnRH拮抗剂LZHN2502在辅助生殖适应症临床Ⅱ期研究中取得显著成果。该研究为多中心、开放性剂量探索试验,结果显示,LZHN2502 40mg每日一次给药,早发LH峰抑制率高达100%,且安全性和耐受性良好,实现了用药方案优化,提升了患者用药依从性。目前全球尚未有口服GnRH拮抗剂上市,LZHN2502研发进度位列...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10